Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | C5 | P01031 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.56 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carprofen SCHEMBL8213384 | 0.92 | PTGS2 (0.71) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL30910956 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL30910975 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL29930903 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL30910972 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL3909 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL3698103 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL3910 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL5055325 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 | |
| Carprofen SCHEMBL29377449 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1MEN1ABCC4C5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108135863-B | EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions | 特拉维夫医疗中心医学研究基础设施和保健服务基金会 | 2021-07-27 | — | — | CN | disclosed |
| EP-2046739-B1 | SUBSTITUTED ANILINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2015-08-26 | — | — | EP | disclosed |
| US-8624022-B2 | Substituted aniline derivatives | UCB PHARMA, S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20120029188-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2012-02-02 | — | — | US | disclosed |
| US-8071582-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20110014271-A1 | Substituted Aniline Derivatives | UCB PHARMA S.A. (BE) | 2011-01-20 | — | — | US | disclosed |
| US-7678785-B2 | Substituted aniline derivatives | UCB PHARMA S.A. (BE) | 2010-03-16 | — | — | US | disclosed |
| EP-2046739-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB Pharma S.A. (BE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008012524-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029188-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | PTGS2 3033/4885PTGS1 3549/4885MEN1 1395/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | PTGS2 2600/4885PTGS1 3219/4885MEN1 552/4885 |
| US-20110014271-A1 | Substituted Aniline Derivatives | NAT1, DPM1, IL4I1 | PTGS2 3033/4885PTGS1 3549/4885MEN1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.